||Last Updated: Nov 17th, 2006 - 22:35:04
Laser probe of a brain pigment's anatomy may offer insight into Parkinson's disease
In a finding that may offer clues about Parkinson's disease, a team led by Duke University researchers used a sophisticated laser system to gain evidence that a dark brown pigment that accumulates in people's brains consists of layers of two other pigments commonly found in hair.
Sep 26, 2006, 23:15
Novel blood test for early detection of Parkinson's, receives national recognition
The research of Dr Kay Double, an NHMRC Senior Research Fellow at the Prince of Wales Medical Research Institute, has received the nation's highest commendation through her inclusion in the NHMRC's 2006 "10 of the Best" booklet.
Sep 1, 2006, 17:29
New genetic model for Parkinson's disease
Researchers at the Karolinska Institute in Sweden are homing in on mechanisms that may explain one set of causes for Parkinson's disease. In mice they have mimicked disturbances of mitochondria thought to be one cause of disease. By genetic means the disturbance of mitochondria - the energy factories of cells - were directed to those nerve cells that produce the transmitter substance dopamine and that die in Parkinson's disease.
Jul 31, 2006, 11:29
Expertise In Brain Stimulation Therapy May Improve Outcomes in Parkinson's Disease
Patients with Parkinson's disease who are undergoing a treatment known as deep brain stimulation may benefit from the direct involvement of a neurologist with expertise both in movement disorders and in deep brain stimulation, according to an article posted online today that will appear in the September 2006 print issue of the Archives of Neurology, one of the JAMA/Archives journals.
Jul 12, 2006, 05:41
Pesticide Dieldrin Linked to Increased Risk of Parkinson's Disease
A team of Emory University researchers has found a connection in laboratory mice between developmental exposure to the pesticide dieldrin (now banned from use) during gestation and lactation and an increased risk of developing Parkinson’s disease (PD). The findings are significant because most studies aimed at determining the disease process in PD have been focused on events occurring during adulthood, not during developmental stages.
Jul 7, 2006, 13:10
ER trafficking defect caused by alpha-synuclein accumulation implicated in Parkinson's
Howard Hughes Medical Institute researchers have pinpointed defects in a critical cellular pathway that can lead to the death of dopamine-producing nerve cells and ultimately symptoms of Parkinson's disease. They have also used several animal models of the disease to identify a new way to rescue dying neurons.
Jun 27, 2006, 02:12
Pesticides exposure associated with Parkinson's disease
In the first large-scale, prospective study to examine possible links between chronic, low-dose exposure to pesticides and Parkinson's disease (PD), researchers at the Harvard School of Public Health (HSPH) have shown that individuals reporting exposure to pesticides had a 70 percent higher incidence of PD than those not reporting exposure. No increased risk of PD was found from reported exposure to other occupational hazards, including asbestos, coal or stone dust, chemicals, acids, or solvents.
Jun 27, 2006, 01:50
Tuberculosis drug PAS may cure Parkinson's-like illness
Researchers have discovered that a drug used to treat tuberculosis apparently cures patients of a Parkinson's-like illness suffered by thousands of mineworkers, welders and others exposed to high levels of the metal manganese.
Jun 7, 2006, 15:37
Stabilizing microtubules with L-AP4 reduces rotenone toxicity
Researchers at the University at Buffalo affiliated with the New York State Center of Excellence in Bioinformatics and Life Sciences have identified a novel agent that can protect neurons involved in Parkinson's disease from being destroyed by the pesticide rotenone.
Apr 19, 2006, 20:01
New Guidelines Improve Diagnosis and Quality of Life for People with Parkinson Disease
New guidelines developed by the American Academy of Neurology aim to educate physicians on the diagnosis and treatment of Parkinson disease and provide people with Parkinson disease an improved quality of life. The guidelines, released at the American Academy of Neurology 58th Annual Meeting in San Diego, Calif., April 1 – 8, 2006, and published in the journal Neurology, were developed through a rigorous, comprehensive review of all of the scientific evidence available on Parkinson disease.
Apr 3, 2006, 15:24
Male gene may explain higher incidence of Parkinson’s in men
Scientists at Prince Henry's Institute, Melbourne, and the University of California, Los Angeles, have discovered that SRY, the male protein that forms the testes is also produced in the brain region affected in Parkinson's disease. This discovery may explain why men are more likely than women to develop this degenerative disorder.
Feb 22, 2006, 01:55
G2019S mutation is major cause of Parkinson's in Ashkenazi Jewish patients
Researchers at the Albert Einstein College of Medicine of Yeshiva University and its Manhattan hospital affiliate, Beth Israel Medical Center, have found that a specific mutation in a single gene is a major cause of Parkinson's disease among Ashkenazi (Eastern European) Jews. The report will appear in the January 26 issue of The New England Journal of Medicine.
Jan 26, 2006, 16:42
Turning off a mutation linked to Parkinson's disease
A group of Northwestern University researchers is developing a novel gene therapy aimed at selectively turning off one of the genes involved in the development of Parkinson's disease. The gene therapy, described in the January online issue of the journal Experimental Neurology, was designed by Martha Bohn and her laboratory group at Northwestern University Feinberg School of Medicine.
Jan 19, 2006, 15:54
Fox Foundation grant funds major gene therapy advance for treatment of Parkinson's disease
An innovative gene therapy approach pioneered by Pennsylvania-based RheoGene Inc. will be further refined and tested in preliminary clinical trials within four years, thanks to a $4.2 million grant from the Michael J. Fox Foundation for Parkinson's Research (MJFF).
Jan 6, 2006, 03:28
Retinal Cell Implants Improve Parkinsonian Motor symptoms
A preliminary study suggests that implants of cells from the human retina improved motor symptoms in patients with Parkinson disease, and they appear to be safe and well tolerated, according to a report in the December issue of the Archives of Neurology, one of the JAMA/Archives journals. Parkinson disease (PD) is a neurodegenerative disorder characterized by tremor, rigidity, postural instability, and slowed ability to start and continue movements. Most patients with PD require therapy with the medication levodopa to control symptoms three to five years after a diagnosis of PD. However, disease progression and long-term oral treatment with levodopa may lead to the development of motor fluctuations and dyskinesias (difficulty or distortion in performing voluntary movements). Human retinal pigment epithelial (RPE) cells produce levodopa and can be isolated from post mortem human eye tissue, grown in culture, and implanted into the brain attached to microcarriers. These implants have ameliorated the motor deficits in animal models of Parkinson disease, according to background information in the article. (The retinal pigment epithelium is the pigment cell layer found in the inner layer of the retina of the eye.)
Dec 14, 2005, 17:16
LRRK2 (Dardarin) - new drug target for Parkinson's
Researchers at Johns Hopkins' Institute for Cell Engineering (ICE) have discovered a protein that could be the best new target in the fight against Parkinson's disease since the brain-damaging condition was first tied to loss of the brain chemical dopamine. Over the past year, the gene for this protein, called LRRK2 (pronounced "lark-2"), had emerged as perhaps the most common genetic cause of both familial and unpredictable cases of Parkinson's disease. Until now, however, no one knew for sure what the LRRK2 protein did in brain cells or whether interfering with it would be possible.
Nov 19, 2005, 18:21
First whole genome map of genetic variability in Parkinson's disease
Mayo Clinic researchers in collaboration with scientists at Perlegen Sciences, Inc. and funded by the Michael J. Fox Foundation for Parkinson's Research have produced the first large-scale whole genome map of genetic variability associated with Parkinson's disease. Their results highlight changes in 12 genes that may increase the risk for Parkinson's disease in some people. Parkinson's disease is a disabling and currently incurable disease that affects millions of people worldwide.
Sep 14, 2005, 02:37
MAO-B inhibitors do not appear to slow Parkinson’s disease progression
FA class of drugs known as MAO-B inhibitors may be effective in improving motor symptoms in people with early Parkinson’s disease and may delay the need for treatment with other drugs, according to a new systematic review of current evidence.
Aug 25, 2005, 06:04
How rotenone destroys the dopamine neurons
Neuroscientists from the University at Buffalo have described for the first time how rotenone, an environmental toxin linked specifically to Parkinson's disease, selectively destroys the neurons that produce dopamine, the neurotransmitter critical to body movement and muscle control.
Aug 25, 2005, 05:20
Loss of nerve fibres reversed in Parkinsons for first time
Analysis of the brain of a patient suffering from Parkinson's Disease has shown that the experimental treatment he received caused regrowth of the nerve fibres that are lost in this disease. The findings are reported in the July issue of Nature Medicine.
Jul 4, 2005, 00:27
Protein formation insights in Parkinson's disease
Researchers at UT Southwestern Medical Center have discovered a mechanism that causes a protein to clump together in brain cells of people with Parkinson's disease, pointing toward a possible treatment for the condition.
Jun 22, 2005, 12:56
Phase I trial of Gene Therapy to Treat Parkinson's Disease Nears Completion
Neurologix Inc. (OTCBB:NRGX) today announced that on April 20, 2005, its scientific co-founder, Michael G. Kaplitt, M.D. Ph.D., presented a clinical update as the Company sponsored landmark Phase I gene therapy trial for the treatment of Parkinson's disease nears completion. This update was given at the 73rd annual meeting of the American Association of Neurological Surgeons (AANS) held in New Orleans.
Apr 24, 2005, 16:34
A “self-management” rehabilitation study for Parkinson’s disease
A “self-management” rehabilitation study at Boston University (BU) Sargent College of Health and Rehabilitation Sciences may help people with Parkinson’s disease restore function and improve quality of life.
Apr 14, 2005, 16:07
New Parkinson's Disease Gene Mutation is Very Common in North Africa
The newest gene for Parkinson's disease, LRRK2, is proving to be a very common cause of familial PD.
Apr 13, 2005, 00:21
Physical exercise linked to lower risk of Parkinsons
Men who were the most physically active at the start of the study cut their risk of developing Parkinson's disease by 50 percent compared to men study participants who were the least physically active. The authors also found that men who reported regularly having engaged in strenuous physical activity in early adult life cut the risk for Parkinson's by 60 percent compared to those who did not.
Feb 22, 2005, 18:13
Most common genetic cause of Parkinson's disease identified
Parkinson's disease, which affects at least 500,000 Americans, is a progressive neurologic disorder that is caused by the degeneration of nerve cells in the portion of the brain that controls movement. Scientists have long suspected genetics plays a role in the onset of the disease. In these studies, the investigators found that a mutation in the gene LRRK2 appears to occur in at least one of every 60 people who have the disease. Overall, the mutation could be responsible for up to 5 percent of Parkinson's disease in people with a family history of the disorder and may account for 1˝ to 2 percent of cases in individuals who do not have a family history of the disease. The researchers found a mutation in one copy of the gene can lead to the disease.
Feb 16, 2005, 19:29
Rasagiline Significantly Reduces 'OFF' Time in Parkinson's - Study shows
"Rasagiline decreased 'off' time and increased the amount of 'on' time,"
said Matt Stern, M.D., professor of neurology at the University of
Pennsylvania and co-principal investigator for the PRESTO study. "The efficacy and tolerability of rasagiline, as demonstrated in this trial, combined with its once-daily dosing, suggest it may be a promising new treatment for PD."
Feb 15, 2005, 08:15
PCBs, fungicide make brain cells vulnerable for Parkinson's
In two papers published in the journal NeuroToxicology (Dec. 2004 and Feb. 2005), the group describes how polychlorinated biphenyls (PCBs) disrupt dopamine neurons, which are the cells that degenerate during the course of Parkinson's disease. Researchers also show that low levels of maneb, a fungicide commonly used in farming, can injure the antioxidant system in those same types of cells. Environmental contaminants might make dopamine cells more vulnerable to damage from normal aging, infection, or subsequent exposure to pollutants, researchers say.
Feb 10, 2005, 17:48
Transplantation of monkey embryonic stem cells reverses Parkinson disease in primates
The replenishment of missing neurons in the brain as a treatment for Parkinson disease reached the stage of human trials over 15 years ago, however the field is still in its infancy. Researchers from Kyoto University have now shown that dopamine-producing neurons (DA neurons) generated from monkey embryonic stem cells and transplanted into areas of the brain where these neurons have degenerated in a monkey model of Parkinson disease, can reverse parkinsonism. Their results appear in the January 3 issue of the Journal of Clinical Investigation.
Jan 4, 2005, 19:28
New route to Parkinson's found in cells' 'garbage disposal' system
Researchers have known that mutations in a key gene called parkin are a major cause of Parkinson's disease (PD). Now they have discovered a new mechanism by which the parkin gene can be compromised, a finding that they say could lead to new drugs for the disorder.
Andrea Lozano, Senior Scientist at the Toronto Western Research Institute, of University Health Network and Professor of Surgery at the University of Toronto and colleagues found that the protein produced by a gene called BAG5 inhibits parkin activity and the action of another protein, called Hsp70, a "chaperone" that works with parkin. They found in studies with rats that BAG5 enhances the death of the dopaminergic neurons targeted by Parkinson's and that inhibiting the gene reduces such death.
Dec 16, 2004, 16:50